Venture investment grew for biopharma and medtech companies in the third quarter of 2023, following a prolific pace in 2021 and a dramatic drop in 2022.
In biopharma, licensing and M&A deals remain down, as do upfront values. In medtech, there are fewer licensing deals, but they’re trending toward higher values.
J.P. Morgan’s biopharma therapeutics and medtech licensing reports explore the movement in each sector, offering insight on industry trends that will shape the end of 2023 and the start of 2024. The reports, powered by DealForma, highlight:
Download the full reports to better understand these dealmaking trends.
Head of Life Sciences, Innovation Economy, Commercial Banking, J.P. Morgan
Head of Healthcare VC Coverage, Commercial Banking, J.P. Morgan
Understanding the middle market: Economic impact and opportunities for growth
Nov 28, 2023
Better supporting U.S. diverse-owned, midsize businesses presents an opportunity to generate more than a trillion dollars in economic activity.
3 takeaways from the 2023 Healthcare Advisory Council
Nov 03, 2023
Patient experience, connectivity and artificial intelligence are on the minds of healthcare leaders as they take on the industry’s mounting financial pressures.
3:19 - Banking
Barry’s: A fitness industry revolution
Nov 01, 2023
25 Years. 84 Studios. One mission: to transform lives worldwide.
Biopharma and medtech venture investments trend up in Q3
Oct 25, 2023
Our Biopharma and Medtech Licensing and Venture Reports explore capital raises, mergers, acquisitions and other trends seen since July.
Trends in venture capital
Oct 12, 2023
Our experts offer insights on how the venture ecosystem is navigating a challenging environment. They also discuss recent signs of life in the IPO market and the increased focus on treasury management by startups.
2:01 - Banking
Birdies: From house-wear to fashionable streetwear
Sep 18, 2023
Meet the founders whose footwear brand is lifting up women—in more ways than one.
It’s time to solve the energy transition’s project development problem
Sep 14, 2023
On the road to COP28, closing the project preparation gap should take center stage
Miss Jessie’s: How the curly haircare brand began making waves
Aug 11, 2023
Founders Miko and Titi Branch started a natural hair movement — and multimillion-dollar business — from their kitchen table.
You're now leaving J.P. Morgan
J.P. Morgan’s website and/or mobile terms, privacy and security policies don’t apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan isn’t responsible for (and doesn’t provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan name.